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Abstract
Background: Improving maternal antiretroviral therapy (ART) retention and adherence is a critical challenge facing
prevention of mother-to-child transmission (PMTCT) of HIV programs. There is an urgent need for evidence-based,
cost-effective, and scalable interventions to improve maternal adherence and retention that can be feasibly
implemented in overburdened health systems. Brief video-based interventions are a promising but underutilized
approach to this crisis. We describe a trial protocol to evaluate the effectiveness and implementation of a
standardized educational video-based intervention targeting HIV-infected pregnant women that seeks to optimize
their ART retention and adherence by providing a VITAL Start (Video intervention to Inspire Treatment Adherence
for Life) before committing to lifelong ART.
Methods: This study is a multisite parallel group, randomized controlled trial assessing the effectiveness of a brief
facility-based video intervention to optimize retention and adherence to ART among pregnant women living with
HIV in Malawi. A total of 892 pregnant women living with HIV and not yet on ART will be randomized to standard-
of-care pre-ART counseling or VITAL Start. The primary outcome is a composite of retention and adherence (viral
load < 1000 copies/ml) 12 months after starting ART. Secondary outcomes include assessments of behavioral
adherence (self-reported adherence, pharmacy refill, and tenofovir diphosphate concentration), psychosocial impact,
and resource utilization. We will also examine the implementation of VITAL Start via surveys and qualitative
interviews with patients, partners, and health care workers and conduct cost-effectiveness analyses.
(Continued on next page)
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: mhkim@bcm.edu
1Baylor College of Medicine International Pediatric AIDS Initiative, Texas
Children’s Hospital, Houston, TX, USA
2Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
Full list of author information is available at the end of the article
Kim et al. Trials          (2020) 21:207 
https://doi.org/10.1186/s13063-020-4131-8
(Continued from previous page)
Discussion: This is a robust evaluation of an innovative facility-based video intervention for pregnant women living
with HIV, with the potential to improve maternal and infant outcomes.
Trial registration: ClinicalTrials.gov, NCT03654898. Registered on 31 August 2018.
Keywords: HIV, ART (antiretroviral therapy), Retention, Adherence, PMTCT (prevention of mother-to-children
transmission), Video
Background
In 2011, Malawi introduced Option B+ (B+), a policy of
test-and-treat universal lifelong antiretroviral therapy
(ART) for pregnant and breastfeeding women. After
implementation, maternal ART uptake increased
sevenfold, the proportion of pregnant women receiving
ART increased from 49% in the pre-B+ era to 89% in
2016, and vertical transmission rates declined [1–6].
Recognizing these benefits, the World Health
Organization endorsed B+, and the majority of high-
prevalence countries are implementing B+. In part, due
to the success of B+, countries have transitioned to uni-
versal treatment for all adults living with HIV infection.
Although the B+ policy resulted in significant gains in
uptake of ART, suboptimal ART adherence and reten-
tion in care remain concerning. Only 59% of pregnant
women initiated on ART were retained in care after 2
years, with the greatest losses occurring soon after initi-
ating treatment [4, 7]. Of those retained, only two-thirds
achieved adequate adherence [4, 8]. Drops in retention
shortly after ART initiation have also been reported
from other high-prevalence settings in the developing
world [9–14].
Barriers to maternal retention and adherence are
multifactorial. B+ was a radical paradigm shift, where in-
dividuals who felt healthy were told to start lifelong
ART. While partner involvement can improve service
uptake and adherence, women received little support in
disclosing their status to partners [15, 16]. For the health
system, rapid ART expansion occurred despite minimal
increases in the health workforce. Overextended staff
had to absorb a new flood of patients, resulting in poor
pre-ART education, long wait times, increased health
care worker (HCW) burnout, and frustrating provider-
patient interactions [8, 17–20].
Several interventions to improve retention and adher-
ence among HIV-positive pregnant and breastfeeding
women have been studied [21–41]. The most effective ex-
amples are supporter interventions (by peer supporters or
community health workers) and the use of short message
service (SMS) technology, but these approaches require
dedicated effort for only modest and temporary gains
[21–32, 35, 42–46]. Other modalities include integration
of prevention of mother-to-child transmission (PMTCT)
services with postnatal care [47, 48], which helps to
address retention further along the cascade. There is a
lack of evidence describing interventions that specifically
target the first encounter, which is critical in preventing
the very early disengagement characteristic of B+.
There is an urgent need for interventions to improve
retention and adherence that can be feasibly imple-
mented in overburdened health systems. Brief video-
based interventions are a promising but underutilized
approach to this crisis. They have a strong track record
in improving health knowledge, supporting partner dis-
closure, increasing treatment adherence, and fostering
behavior change among low literacy patients [49–55].
Video interventions are scalable due to limited costs
after creation [56]. Messages can be woven into engaging
storylines, piloted to ensure cultural relevance, and de-
livered at critical teachable moments [53]. Videos can be
provided in high-volume clinics to deliver standardized
messages while freeing up HCW time. While video-
based interventions have potential to address barriers to
ART retention and adherence, they have seen limited
use in Africa’s HIV pandemic.
In recognizing the critical need for evidence-based,
cost-effective, and scalable interventions to improve ma-
ternal adherence and retention, our study team devel-
oped a brief video-based intervention that provides
pregnant women living with HIV a VITAL Start (Video
intervention to Inspire Treatment Adherence for Life) at
the critical moment before committing to lifelong ART.
The pilot demonstrated that the VITAL Start was very
feasible to implement, highly accepted by both pregnant
women and HCWs, and resulted in excellent knowledge
acquisition and better short-term self-reported adher-
ence as compared to the control [57]. In the present
trial, we aim to rigorously evaluate the effect of VITAL
Start compared to standard of care (SOC) on the pri-
mary composite outcome of retention and adherence in
a multisite randomized controlled trial. If effective,
VITAL Start offers an innovative, scalable tool to ad-
dress the current crisis of maternal retention and adher-
ence while supporting the overburdened health system
in Malawi and similar settings by liberating HCW time.
Methods/design
This randomized controlled trial will evaluate the effect-
iveness of the VITAL Start intervention on the primary
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composite outcome of retention and adherence at three
sites in Malawi. These methods are based on protocol
version 4.0 (updated on 23 August 2018). Figure 1, Study
Flowchart.
Trial setting
The trial will take place in Malawi, a landlocked country
of 17 million people in sub-Saharan Africa. Malawi’s per
capita gross national income is $340 USD, and it has an
adult literacy rate of 62% [58, 59]. Almost all pregnant
women (95%) attend an antenatal care (ANC) clinic at
least once in pregnancy, and HIV status is determined in
more than 90% of ANC attendees through a routine
opt-out approach [3, 60]. Adult HIV prevalence in
Malawi is approximately 11%, and combination ART is
free for all patients with a confirmed diagnosis (defined
as two serial positive results from rapid antibody-based
tests on whole blood). The most commonly used first-
line regimen for all patients (including pregnant women)
is a once-daily fixed dose combination of efavirenz, lami-
vudine, and tenofovir disoproxil fumarate.
The trial will take place at three sites: two urban
health facilities in the capital of Lilongwe (Area 25 and
Kawale Health Centers) and one rural district hospital in
the southern district of Mangochi (see Table 1). All sites
are high-volume public Ministry of Health (MOH) facil-
ities that were selected in consultation with the MOH.
Recruitment of participants
We will recruit 892 pregnant women living with HIV
presenting to ANC clinics. Research assistants (RAs)
assigned to each facility will deliver health talks to all pa-
tients attending ANC before the clinic begins, describing
the trial and inviting interested patients to participate.
RAs will also work with facility staff to identify eligible
participants. To be eligible for trial participation, individ-
uals must meet all of the following inclusion criteria:
Fig. 1 Study Flow Diagram, as per Consolidated Standards of Reporting Trials (CONSORT)
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1. Willing to provide informed consent
2. Currently pregnant, verified by palpation or urine
pregnancy test if not palpable
3. HIV-positive, verified by two positive rapid
antibody-based tests
4. Able to understand Chichewa
5. Age 18 or older. Individuals age 16–17 may
participate only if they are either married or have a
child
6. Not currently on ART. Individuals previously on
ART but who disengaged from care prior to the
index pregnancy are eligible
7. Plans to stay in the trial catchment area and receive
ART and ANC services from the health facility of
enrollment for at least 6 months.
Exclusion criteria include any of the following:
1. Already on ART
2. Pre-existing psychiatric comorbidity that would
impair ability to provide informed consent.
Participants will be randomized in a 1:1 fashion to the
SOC or VITAL Start arms. In terms of HIV/ART care
received, the only difference between the arms will be
the type of pre-ART counseling received.
Standard-of-care pre-ART counseling
Participants randomized to SOC will receive the SOC
pre-ART initiation education from a clinic health worker
using the National ART Counseling Flip Chart [61], an
educational tool with pictures on one side and key mes-
sage prompts on the other. Topics include the basics of
ART and the importance of adherence. Complete review
of the flip chart typically takes one hour. To reduce con-
tamination, VITAL Start and SOC will be delivered in
separate areas.
VITAL Start intervention pre-ART counseling
Participants in the VITAL Start arm will receive a 37-min
intervention (27-min video and 10-min scripted RA-
delivered individual counseling session). The video, titled
Chiyembekezo (“Hope” in Chichewa), was developed
through an iterative multistep process involving a team of
persons living with HIV, researchers, clinicians, MOH
staff, and other stakeholders. In conceptualizing the video,
three behavior-determinant models were selected based
on their demonstrated ability to promote behavior change
in HIV/STD interventions:
1. Social cognitive theory, to address social influences
2. The theory of planned behavior, to address the
cognitive aspects of how patients may conceptualize
health threats and appraise barriers to or facilitators
of lifelong retention and adherence to ART
3. The information-motivation-behavioral (IMB) skills
model, which asserts that knowledge must be linked
to both motivation and behavioral skills to over-
come barriers critical to achieve adherence [57].
Development of video content was through a commu-
nity participatory approach to ensure that the content
was acceptable and engaging. Focus groups with people
living with HIV/AIDS and local clinicians identified
three key subject areas the video should target: (1) the
importance of starting lifelong ART while feeling
healthy; (2) management of ART side effects; (3) partner
disclosure.
An advisory group of HCWs, ART providers, and
MOH staff consulted at all stages of video development.
Content was generated through a partnership with In
Tune for Life, a nonprofit organization with expertise
producing health promotion videos. The finished video
depicts an urban Malawi setting with a female protagon-
ist who is pregnant and newly diagnosed with HIV at
ANC clinic. The film depicts her anxieties about her
health, protecting her baby, disclosing to her husband,
and remaining on ART for life. A nurse and close friend
encourage her to disclose her status to her partner and
remain adherent. Through their reassurances, the
protagonist is empowered in her relationship with her
husband and prepared to take ART for life.
Interventions for both arms (VITAL Start and SOC)
occur upon trial enrollment at the ART initiation visit.
Table 1 Trial site characteristics
Site HIV
prevalence
at ANC (%)
HIV-positive women attending ANC per year, n (%) Proportion retained after initiation (%)
On ART Not on ART Total 6 months 12 months
Kawale Health Center 12.4a 191 (38.9) 300 (61.1) 491 68b 57b
Area 25 Health Center 11.2 303 (51.9) 281 (48.1) 584 62 58
Mangochi District Hospital 12 288 (47.8) 315 (52.2) 603 46c 53c
All data from Malawi Ministry of Health HIV Unit quantitative data reports, calendar year 2015 unless otherwise noted due to missing data aIncluded data from
2014 quarter 4 due to missing data in 2015 quarter 1 bIncluded data from 2014 quarter 3 due to missing data in 2015 quarter 1 cUsing data from calendar
year 2016
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Due to the one-off nature of the trial intervention, there
are no criteria for discontinuing or modifying allo-
cated interventions for a given trial participant after
randomization. Participants will not be allowed to
switch arms if they desire a different intervention
after allocation. All other clinical care will be carried
out according to MOH guidelines.
Contamination and intervention fidelity
To help ensure treatment fidelity and reduce contamin-
ation, we have adopted practices recommended by the
National Institutes of Health (NIH) Behavior Change
Consortium Treatment Fidelity Workgroup in five areas:
trial design, training, delivery of treatment, and receipt of
and enactment of treatment skills [62]. Multiple strategies
were developed, tested, and revised; key strategies are
listed in Table 2. In brief, we will use two fidelity checklists
to monitor, measure, and ensure fidelity to the VITAL
Start intervention. The two checklists are an Observer
Intervention Fidelity Checklist (completed by an RA ob-
serving the VITAL Start intervention) and a Self-
Administered Intervention Fidelity Checklist (completed
by the RA who is administering the intervention). An
overall fidelity score will be determined to assess the level
of fidelity maintained based upon four key measurement
criteria as outlined in Dusenbury, et al. [65]: adherence,
dose, quality of delivery, and participant responsiveness.
Other fidelity measures are outlined in Table 2.
Participant follow-up surveys
After enrollment, participants will attend trial visits at
months 1, 3, 6, and 12 for a total of five trial visits.
Participants will be provided with the equivalent of $5
USD for transport reimbursement for each trial visit.
Follow-up surveys will be completed at a time and place
separate from routine ART refill visits.
Measures
A full list of measures and a schedule of assessments are
outlined in Table 3. See also the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) checklist, provided as Additional file 1. The
primary outcome is a composite measure of retention
and viral suppression at 6 and 12 months. Participants
will be considered retained in care if they are verified by
clinic records as active on ART within 2 months of the
last trial visit. Viral suppression will be measured as viral
load < 1000 copies/mL. Retention was chosen as a
primary outcome due to its strong association with ad-
herence [81]. Viral suppression as a marker of adherence
was included in the primary outcome because viral
suppression is the clinical goal of ART and leads to de-
creased HIV-related mortality and morbidity [82].
We will also examine several secondary outcomes.
Adherence will be further measured by self-reported ad-
herence, pharmacy refill data, and tenofovir diphosphate
Table 2 Methods to reduce contamination during all phases of
the proposed research and ensure intervention fidelity
Trial design and pre-implementation
▪ Increased sample size to account for potential contamination (up to
15%)
▪ Focus group discussions and literature reviews have explored types,
extent of, and measures to reduce possible contamination sources.
Overall risk of contamination deemed to be very small
▪ Focus group discussions identified video recall items to measure
contamination
▪ Trial staff and trial clinic training emphasizes the implications of
contamination, how to avoid it, how to address questions using non-
biased explanations, and the need to ensure VITAL Start and SOC are
delivered in separate places
Implementation
▪ VITAL Start and SOC occur in separate locations, and intervention is
delivered by trained RAs
▪ Participants will be escorted between counseling and survey locations
▪ Level and extent of patient-reported contamination is measured at
follow-up visits
▪ Video is on password-protected tablet that is stored at the health facil-
ity and not available through other channels
▪ Information packs with VITAL Start materials are clearly labeled and
stored separately from SOC materials
▪ Any accidental contamination by trial or health facility staff will be
recorded on Unanticipated Problems Forms that are reviewed monthly
at site-level meetings and supervisions
▪ Site Research Supervisor to confirm trial participants only receive
assigned intervention
▪ Rationale and techniques for reducing contamination discussed at
monthly site meetings with health facility and trial staff
▪ Information regarding participant’s trial arm allocation is kept in a
locked drawer that can only be accessed by RA
▪ Contamination is measured quarterly as a component of checklist to
measure the degree of fidelity [63]
Strategies to ensure treatment fidelity
▪ Fidelity checklists completed by RA (self-administered) and observer.
Key issues discussed at quarterly staff meetings
▪ Intervention sessions audio recorded, and 10% reviewed centrally
▪ Electronic time-stamps of session start and end time and bi-monthly
supervisions by trial coordinator
▪ Unannounced trial coordinator visits
▪ Plans for implementation setbacks which include two providers (RAs)
per site, back-up tablets, paper forms, power banks, and back-up phys-
ical space for intervention implementation
Analysis
▪ If contamination occurs, we will perform contamination-adjusted
intention-to-treat analysis [64]
▪ The degree, nature, and effects of contamination will be included in
final manuscripts
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concentration at 12 months. Tenofovir diphosphate
(TFV-DP) is a metabolite of tenofovir that allows estima-
tion of average adherence over the preceding 2 weeks.
Use of TFV-DP will allow detection of small, clinically
significant differences in adherence between groups that
may be missed by viral load testing alone [83].
To critically examine the implementation of VITAL
Start, we will also examine participant satisfaction, inter-
vention fidelity, contamination, and time-motion data.
Guided by social action theory [84], we will also assess a
series of behavioral, mental health, and psychosocial
measures during the trial as potential mediators or mod-
ifiers of the intervention’s effect as well as potential
independent factors, which may influence adherence be-
haviors. These include assessments of HIV knowledge,
whether a patient is a new ART initiator or re-initiating
ART, measures of depression, alcohol and substance use,
intimate partner violence, and availability of social
support. Finally, we will collect financial data alongside
clinical outcomes to assess the cost-effectiveness of
VITAL Start compared to SOC.
The issue of distinguishing trial retention from reten-
tion in clinical care deserves special mention in this trial,
where retention in clinical services is a primary outcome,
and efforts to promote trial retention may have unin-
tended consequences. Trial staff will collect telephone
numbers and/or physical address details from partici-
pants willing to provide this information. When a par-
ticipant is absent for a trial visit, staff will trace her first
by telephone, and will make three valid attempts (de-
fined as speaking with the participant) or will attempt
daily for a week, whichever comes first. After phone tra-
cing, staff will attempt to visit the participant at home,
and will make up to three valid attempts. Participants
will be allowed to complete trial questionnaires at home
during these tracing attempts if they desire and a secure
Table 3 VITAL Start trial outcomes and schedule of measures
Schedule (month number) 0 1 3 6 12
Informed consent x
Allocation x
Intervention x
Aim 1: Retention and adherence (viral load [VL] < 1000 copies/ml) at 12 months
Retention in care (data abstraction from facility records) x x x x
Viral suppression (VL < 1000 copies/ml) x x
Aim 1b: Behavioral adherence
Self-reported adherence [66, 67] x x x x
ART side effects x x x x
Pharmacy refill data abstraction [68] x x x x
Tenofovir diphosphate level x
Aim 1c: Knowledge and psychosocial impact
HIV/ART knowledge and attitudes survey [69] x x x
Adherence self-efficacy [70, 71] x x x x
Motivation and behavior skills assessment: LifeWindows tool [72] x x x
Self-reported partner disclosure and World Health Organization intimate partner violence survey [73] x x x x
Multidimensional Scale of Perceived Social Support (MSPSS) [74] and self-reporting questionnaire [75] x x x x
Shortened Alcohol Use Disorders Identification Test [76] and Drug Use Disorders Identification Test [77] x x x x
Patient-Provider Relationship Scale [78, 79] x x
Aim 2: Implementation outcomes
Participant satisfaction surveys x
Interviews with participants, partners, health care workers x x x x x
Trial fidelity evaluations x
Contamination assessment x x x
Time-motion assessments in line with Suggested Time And Motion Procedures (STAMP) checklist [80] x
Aim 3: Cost-effectiveness analysis. Data collected throughout trial period. Start-up: video creation, training, tablets and accessories (security cable,
power bank). Recurring: tablet maintenance; personnel time and salaries
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location is available for the interaction. All tracing
attempts will be recorded to allow analysis of tracing
attempts according to trial arm and controlling for
tracing attempts, if necessary.
Participants who transfer to a different facility will not
be terminated from the trial unless they withdraw
consent or are found to have died. This decision reflects
the highly mobile nature of the trial population that we
have observed in previous studies. By keeping partici-
pants enrolled, they can easily transition back into the
trial if they move back to the catchment area or are
willing to continue attending trial visits. If a subject is
discontinued at any time after entering the trial, the trial
team will try and ensure that the subject completes the
Final Visit survey and procedures.
Sample size
The sample size calculation is based on a comparison of
the proportions of those in the intervention versus SOC
arms who reach the combined primary endpoint at 12
months after maternal ART initiation. A combination of
various scenarios was considered for retention in care
(50–90%), maternal viral suppression (50–90%) among
those retained, and contamination rate (0–15%). A
difference of 15% was selected as the smallest differ-
ence that would be of clinical significance.
For the primary analysis in all subjects, accounting for
up to a 15% contamination (pilot data suggested 0%)
and 5% attrition rate (based on transfer-out rates from
MOH data at trial clinics in 2016) [3], and assuming a 1:
1 allocation ratio to achieve 90% power to detect a
minimum difference of 15% between the control and
intervention groups, 796 subjects are required (398/398
per arm) at a significance level of 0.025 to account for
multiple comparisons. We further increased this by 12%
to 892 total (446 per arm) to account for a potential
change to national guidelines to recommend dolutegravir-
based regimens as first-line ART. The higher potency of
dolutegravir-based regimens may allow higher rates of
viral suppression at lower adherence levels, therefore im-
proving overall viral suppression and making a difference
between arms more difficult to detect.
Assignment of interventions and blinding
Participants will be randomly assigned in a 1:1 fashion
stratified by clinic proportional to the number of
potential eligible participants at that site. Smith’s
randomization algorithm will be applied for random as-
signment to VITAL Start or SOC to reduce imbalance
throughout the randomization process [85]. The primary
trial biostatistician will generate serial random codes for
each clinic and place them on a sequential list that will
be maintained by the trial coordinator. Assignments will
be provided to RAs in opaque sealed numbered
envelopes to be opened sequentially prior to administra-
tion of the baseline survey. If a participant refuses to
participate in the trial after randomization, the next sub-
ject will not replace her. The randomized participant
who refused participation will be included in the
intention-to-treat (ITT) analysis. Due to the nature of
the intervention, RAs, clinic staff, and participants will
not be blinded. Separate research staff (outcome asses-
sors) will remain blinded and conduct the outcome as-
sessments including follow-up surveys. They will not be
informed of the participants’ group assignment. All trial
investigators will also remain blinded. After data collec-
tion is complete and the database cleaned and locked, a
research team member will break the randomization
code to input the group allocation within the pre-
existing data set and enable between-group analyses.
Strategies for ensuring fidelity to the VITAL Start
intervention are described in detail in Table 2. Fidel-
ity will be quantitatively assessed by both the RA per-
forming the counseling and an RA observing the
counseling session. Contamination may occur if par-
ticipants who receive the VITAL Start intervention
discuss elements of the video with participants who
received standard of care (SOC). Pilot data suggested
little to no risk of contamination with the contamin-
ation reduction procedures that will be used in this
trial (Table 2). However, in case contamination does
occur, we will assess the prevalence, magnitude, and
source of contamination. Participants will complete a
contamination assessment at months 1, 6, and 12,
and we will account for contamination via a
contamination-adjusted ITT analysis [64].
Data collection and management
All data will be collected on electronic case report forms
(CRFs) by trained trial staff using electronic CRFs on
tablets and will be monitored weekly via data checks by
the study team. We elected to use electronic CRFs to
improve both efficiency and data quality through the use
of internal checks and automated skip patterns [86].
Backup paper CRFs will be maintained at all sites. The
use of tablets also allows us to use an audio computer-
assisted self-interview approach to assess self-reported
adherence to medication, theoretically improving partici-
pants’ comfort with responding truthfully to these ques-
tions [87]. RAs will administer surveys at baseline; all
follow-up surveys will be conducted by blinded outcome
assessors at a location separate from the ART clinic
where they receive their ART medications.
All tablets will be encrypted and password-protected
and will use a secure connection to transfer data to a
central server on a daily basis. A full list of data sources
and schedule of assessments can be found in Table 3.
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Statistical methods
The primary analysis will be conducted as ITT. If there
are exceptional circumstances which could lead to ex-
cluding randomized subjects from the ITT population
without the possibility of introducing bias (e.g., an ineli-
gible patient is mistakenly enrolled), a modified ITT
(mITT) analysis will be used as the primary analysis. A
statistical analysis will be performed at the end of the
trial; no statistical interim analysis is planned.
Baseline characteristics by arm will be displayed using
descriptive statistics. The primary outcome measure
(maternal ART retention and viral suppression) is a bin-
ary variable, and it will be compared by chi-square tests
at 12 months, and followed by logistic regression to
study the association between intervention and outcome
while controlling the baseline prognostic factors of the
main outcome. The main exposure variable and any fac-
tor deemed to be clinically relevant will be forced into
the model regardless of the statistical significance. Sec-
ondary outcomes include components of the composite
outcome, self-reported adherence, pharmacy refill data,
ART knowledge and self-efficacy, motivation and behav-
ior skills, partner disclosure, and social support, etc. For
the 12months outcome, chi-square tests and two-
sample t tests will be used. For repeated measures, the
generalized estimating equations (GEE) method and
linear mixed models will be used to examine differences
in trajectories over time between the intervention and
control groups while accounting for the correlation
among repeated measures from the same subject.
Additionally, for time-to-event outcomes, such as time
to partner disclosure, we will conduct survival analysis
using the Kaplan-Meier (KM) method with log-rank test
and Cox proportional hazard models including the
covariates. A p value of 0.05 will be deemed statistically
significant and a p value of 0.1 regarded as a statistical
trend. All analyses will be performed using SAS software
(SAS Institute, Inc., Cary, NC, USA).
Cost-effectiveness analysis
The MOH will be the main implementer of the VITAL
Start intervention as well as SOC pre-ART counseling.
Therefore, we will assess costs from the provider (MOH)
perspective. We will use both micro- and macro-based
approaches as appropriate to identify and quantify inter-
vention resources [88–90]. Retrospectively, we will
extract information on resources expended for video
design and production from inventory and other pro-
gram documents. Unit prices will be obtained from
account records or from local retailers. To measure staff
time devoted to pre- ART counseling, we will perform
time-motion assessments in line with the Suggested
Time And Motion Procedures (STAMP) [80, 91, 92].
We will sample sufficiently to account for potential
sources of heterogeneity such as trial clinic and provider.
The value of staff time will then be estimated as the
product of their gross salary and share of time allocated
to intervention/pre-ART counseling.
We will calculate the incremental cost-effectiveness
ratio (ICER) for the primary outcome of economic
interest. The ICER is the difference in costs between two
interventions divided by the difference in their effects,
and it can be interpreted as the incremental price of a
unit health effect from the intervention under study, as
compared to the alternative. We will conduct one-way
and multiway sensitivity analyses to model cost-
effectiveness under various conditions, such as lower
pricing of video production, mode of delivery, tablets,
and alternate health care worker (HCW) cadres to
deliver the intervention. Finally, we will conduct
probabilistic sensitivity analyses using bootstrapping
methods to ascertain the robustness of our results to
extreme assumptions/scenarios. Based on emerging
literature [89, 93], we will determine cost-effectiveness
by comparisons with published ICERs for other com-
monly implemented HIV interventions in Malawi and
southern Africa, as well as with gross domestic product
(GDP)-based thresholds (0.5× and 1× the Malawi per
capita GDP of $487) [94].
Monitoring
Blinded data monitoring will be conducted using de-
scriptive statistics for quality assessment purposes, such
as monitoring subject accrual and compliance as well as
identifying outstanding values, etc., for data quality
control. The results will be displayed for follow-up
measures for the combined group, and otherwise by
blinded treatment groups. We will monitor for overall
trends in retention weekly. All unanticipated problems
and adverse events will be recorded on designated CRFs
and reported to the principal investigator (PI) and ap-
propriate regulatory bodies. All potential adverse events
will be reviewed weekly by the PI, trial coordinator, and
research supervisors. The data manager will review trial
data weekly. A stakeholder advisory group (SAG) com-
prising trial site supervisors, trial site clinical staff, and
community members will meet twice a year to provide
input on study implementation. In addition, an external
monitor will evaluate trial operations annually.
Measures to ensure intervention implementation and
fidelity are detailed in Table 2.
Ethics and dissemination
This trial has been approved by the Baylor College of
Medicine Institutional Review Board (IRB; protocol H-
39785) and the Malawi National Health Sciences
Research Committee (NHSRC; protocol 16/05/1593). If
the investigators elect to make important modifications
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to the protocol, amendments will be submitted to both
the Baylor IRB and Malawi NHSRC.
Informed consent will be obtained in writing from all
participants by trial site staff using forms in Chichewa
approved by both the Baylor IRB and Malawi NHSRC. A
staff member fluent in Chichewa will be responsible for
reviewing the form in detail and eliciting any questions
before the participant signs. If the patient is unable to
read, staff will read the consent form to the participant
in its entirety, the participant will mark her thumbprint
to indicate consent, and the process must be witnessed
by a third party not involved in the trial.
Confidentiality will be prioritized and will include the
following measures specific to our intervention and trial
population:
1. We will use only study identification numbers for
all data collection and analysis.
2. All electronic data will be secured through
encryption, and paper data will be secured through
locked cabinets stored in locked study offices.
3. We will ensure that all staff are trained to the
highest standards of confidentiality and data
security procedures through appropriate online
modules provided by the Collaborative Institutional
Training Initiative (CITI).
4. When conducting home visits, staff will not wear
anything that shows they are from a health facility
or the trial, and they will not carry information
identifying the participant as having HIV, to
minimize unintentional risk of disclosure.
Ancillary and post-trial care
All participants will receive free lifelong ART as per
Malawi MOH guidelines. Lab results from the trial (viral
load measurements and TFV-DP concentration) will be
provided to participants after the final trial visit in
writing, along with a brief interpretation of the results
for the participant’s clinician.
We will ensure that trained psychosocial counselors
will be available to support participants who screen
positive for current intimate partner violence, depres-
sion, or suicidality.
Dissemination policy
Results will be reported to the MOH and local stake-
holders, as well as at local and international conferences.
Results will also be submitted to peer-reviewed journals.
Authorship eligibility will be guided by the International
Committee of Medical Journal Editors criteria [95].
Discussion
By evaluating a brief, low-cost, scalable and locally devel-
oped and culturally tailored tool to promote adherence
and retention, this trial has the potential to streamline
ART counseling in resource-limited settings. In contrast
to many other interventions, it also has the potential to
liberate precious HCW time, thereby supporting health
systems in meeting the needs of their patients.
This trial utilizes multiple methods to examine adher-
ence, including two methods of behavioral adherence
(self-report and pharmacy pill count), as well as viral
load and TFV-DP testing. Due to TFV-DP’s longer half-
life, its concentration is a measure of average adherence
over the previous 2 months, allowing estimation of the
average number of doses missed per week. Use of this
marker thereby allows reliable detection of clinically
significant between-group differences in adherence. This
trial also utilizes a combined outcome of retention and
viral suppression. Further, the trial not only seeks to
evaluate effectiveness, but it also aims to critically exam-
ine the implementation of a new intervention through
qualitative interviews, validated questionnaires, time-
motion measures, and cost-effectiveness analysis, among
other methods.
As with any research design, the trial has potential
limitations. In studies where a primary outcome is
retention, caution is warranted in determining how
participants are traced for missed trial visits, since the
act of missed trial visit tracing plausibly affects clinical
retention. We attempted to address this concern by
outlining precisely how many tracing attempts for
missed trial visits should be done, and we developed a
mechanism for recording all missed trial visit tracing
attempts to allow incorporation of this effect into the
final analytic model as necessary.
A small pilot study suggested the VITAL Start inter-
vention to be an acceptable, feasible approach that
resulted in excellent knowledge acquisition and better
short-term self-reported adherence as compared to the
control. This multisite randomized controlled trial will
allow rigorous evaluation of this promising approach to
improve ART adherence.
Trial status
The protocol is version 4.0 dated 23 August 2018. Trial
enrollment started in October 2018, and recruitment will
be completed in March 2021.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4131-8.
Additional file 1. SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents.
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